翰森制药(03692) - 2024 - 年度业绩

Financial Performance - The company reported revenue of approximately RMB 12.261 billion for the year ending December 31, 2024, representing a year-on-year growth of approximately 21.3%[4] - Profit for the same period was approximately RMB 4.372 billion, an increase of about 33.4% compared to the previous year[15] - Basic earnings per share were approximately RMB 0.74, an increase of approximately 33.3% compared to the previous year[4] - Revenue for the year ended December 31, 2024, reached RMB 12,260,814 thousand, a 21.4% increase from RMB 10,103,806 thousand in 2023[77] - Gross profit for 2024 was RMB 11,155,406 thousand, up from RMB 9,072,943 thousand in 2023, reflecting a significant growth in profitability[77] - Net profit for the year was RMB 4,371,825 thousand, representing a 33.4% increase compared to RMB 3,277,503 thousand in 2023[79] - The group's profit before tax rose to RMB 3,327,665,000 in 2024, compared to RMB 2,680,840,000 in 2023, reflecting a growth of 24.2%[90] Revenue Breakdown - Sales revenue from innovative drugs and collaborative products reached approximately RMB 9.477 billion, an increase of approximately 38.1% year-on-year, accounting for about 77.3% of total revenue[4] - Revenue from the oncology segment was approximately RMB 8.122 billion, making up about 66.2% of total revenue[18] - The anti-infection segment generated revenue of approximately RMB 1.464 billion, contributing about 11.9% to total revenue[18] - The central nervous system segment reported revenue of approximately RMB 1.379 billion, representing about 11.3% of total revenue[18] - The metabolic and other diseases segment achieved revenue of approximately RMB 1.296 billion, accounting for about 10.6% of total revenue[18] Research and Development - Research and development expenses amounted to approximately RMB 2.702 billion, up approximately 28.8% year-on-year, representing about 22.0% of total revenue[4] - Over 60 clinical trials for innovative drugs are currently ongoing, with 8 new candidates entering clinical research stages during the reporting period[37] - The company has published multiple research findings on ShengLuoLai® in prestigious journals and conferences, focusing on its mechanism of action and clinical studies[33] Product Approvals and Developments - The company received clinical trial approval for the innovative drug HS-10501, intended for the treatment of type 2 diabetes and adult obesity[6] - The innovative drug Amelot® received its third NDA acceptance from NMPA for use in NSCLC patients with specific mutations[9] - The innovative drug Amelotin® has been approved for three indications and was successfully included in the 2024 National Medical Insurance Directory[21] - The product XinYue® (Inalizumab injection) received NMPA approval for treating adult patients with AQP4 antibody-positive NMOSD on March 14, 2022, and was included in the national medical insurance catalog in January 2023[25] - HS-20093, a B7-H3 targeted ADC, has entered Phase III clinical trials for small cell lung cancer and has shown strong anti-tumor activity in preliminary studies[40][41] Licensing Agreements - A licensing agreement was established with Zhuhai Pumis Biotechnology Co., granting the company exclusive rights to develop and commercialize HS-20117 globally[6] - The company entered into a global exclusive licensing agreement with Merck Sharp & Dohme LLC for the development of the investigational GLP-1 receptor agonist HS-10535[13] - The company has entered into a licensing agreement with Promis to develop and commercialize the bispecific antibody HS-20117 globally, currently in Phase I clinical trials[49] - The company has secured a licensing agreement with LUPON Pharmaceuticals for HS-10561, a BTK inhibitor, with clinical trials for chronic spontaneous urticaria expected to commence in February 2025[51] Corporate Governance and Sustainability - The company maintained an MSCI ESG rating of AA and was included in the S&P Global Sustainable Development Yearbook 2025, ranking first in the Chinese pharmaceutical industry[13] - The company plans to continue reviewing and enhancing its corporate governance practices to ensure compliance with the corporate governance code[110] - The audit committee, consisting of three independent non-executive directors, reviewed the audited performance for the year ending December 31, 2024[112] Cash Flow and Financial Position - The group reported a net cash inflow from operating activities of RMB 3.862 billion for the year ending December 31, 2024[62] - As of December 31, 2024, the group had cash and bank deposits totaling RMB 22.622 billion, an increase from RMB 22.435 billion as of December 31, 2023[63] - The group's asset-liability ratio was approximately 9.4% as of December 31, 2024, a decrease from 21.9% as of December 31, 2023[63] - Total assets less current liabilities increased to RMB 28,962,631 thousand in 2024 from RMB 26,176,230 thousand in 2023, indicating a stronger financial position[81] Dividends and Shareholder Returns - The declared final dividend for 2023 was RMB 768,760,000, significantly higher than RMB 268,852,000 for 2022, representing a 186.5% increase[96] - The company announced a final dividend of HKD 0.1353 per share for the year ending December 31, 2024, down from HKD 0.1422 in 2023[115] - The total dividend for the year 2024, including the interim dividend, amounts to HKD 0.3363 per share[115]